Pedro Canals-ferrat MD in New York, New York

Home New York New York

Pedro Canals-ferrat MD has Anesthesiology as his primary medical specialty. Their primary office is: 1 Gustave L Levy Pl in New York, New York.

They're a part of the: Fpa Hospital Based medical group which has around 499 members. You can call their office at 212-241-6426 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Sorry, his university is not listed and graduated in 1988 (around 36 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.

Pedro Canals-ferrat MD Office Phone and Directions

Pedro Canals-ferrat MD
Fpa Hospital Based
1 Gustave L Levy Pl
New York, New York 10029
212-241-6426

Patient Ratings
Please rate your experience with Pedro Canals-ferrat MD below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 212-241-6426

Enter a starting address:

Healthcare Info for Pedro Canals-ferrat MD

Medical School: Sorry, his university is not listed
Graduation Year: 1988
The Primary Medical Specialty for Pedro Canals-ferrat MD is listed as: Anesthesiology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 36
PAC (PECOS ID)#: 4789622135
NPI #: 1811942709
NPI Created On: 05/23/2006
NPI Last Updated Listed as: 04/03/2015
Primary Taxonomy Code: 207L00000X
License Number:
210040-1
Listed Gender: Male

They took part in the Medicare Physician Quality Reporting System (PQRS).

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $11

Number of Payments:: 1

Form of Payment: In-kind items and services

Record ID:: 849479927

Being Disputed:: No

Product Related: Yes

Drug or Biological: Drug

Product Category #1: Pain Management

Name of Drug #1: Exparel

Open Associated Drug #1: 65250-266-09